Literature DB >> 28940909

Postimplantation ventricular ectopic burden and clinical outcomes in cardiac resynchronization therapy-defibrillator patients: a MADIT-CRT substudy.

Anne-Christine Ruwald1,2, Mehmet K Aktas1, Martin H Ruwald1,3, Valentina Kutyifa1, Scott McNitt1, Christian Jons4, Suneet Mittal5, Jonathan S Steinberg1,5, James P Daubert6, Arthur J Moss1, Wojciech Zareba1.   

Abstract

BACKGROUND: Frequent ventricular ectopy on preimplantation Holter has been associated with attenuated benefit from cardiac resynchronization therapy (CRT). However, it is unclear whether ectopic burden measured post-CRT implantation can be utilized to evaluate long-term prognosis. We aimed to describe the association between post-CRT implantation ectopic burden and subsequent risk of clinical outcomes.
METHODS: At the 12-month follow-up visit, 24-hour Holter recordings were performed in 698 CRT-D patients from the MADIT-CRT study. The mean number of ventricular premature complexes (VPCs/hour) was calculated. High ectopic burden was defined as >10 VPCs/hour and low burden as ≤10 VPCs/hour. Multivariate Cox proportional hazards models were utilized to assess the association between 12-month ectopic burden and the risk of the end points of heart failure (HF) or death and ventricular tachyarrhythmias (VT/VF).
RESULTS: At 12 months, 282 (40%) patients presented with low ectopic burden and 416 (60%) patients presented with high ectopic burden. The 3-year risk of HF/death and VT/VF was lower in patients with a low burden (7% and 8%) and significantly higher (25% and 24%) in patients with high burden. In multivariate analyses, patients with a high ectopic burden had approximately threefold increased risk of both HF/death (HR=2.76 [1.62-4.70], p < .001) and VT/VF (HR=2.79 [1.69-4.58], p < .001).
CONCLUSION: In CRT-D patients with mild heart failure, high ectopic burden at 12-month follow-up was associated with a high 3-year risk of HF/death and VT/VF and threefold increased risk as compared to patients with low burden. Ectopic burden at 12 months may be a valuable approach for evaluating long-term prognosis.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  appropriate therapy; cardiac resynchronization therapy; death; heart failure; premature beats; ventricular ectopy; ventricular tachycardia

Mesh:

Year:  2017        PMID: 28940909      PMCID: PMC6931682          DOI: 10.1111/anec.12491

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


  21 in total

1.  Cardiac resynchronization in chronic heart failure.

Authors:  William T Abraham; Westby G Fisher; Andrew L Smith; David B Delurgio; Angel R Leon; Evan Loh; Dusan Z Kocovic; Milton Packer; Alfredo L Clavell; David L Hayes; Myrvin Ellestad; Robin J Trupp; Jackie Underwood; Faith Pickering; Cindy Truex; Peggy McAtee; John Messenger
Journal:  N Engl J Med       Date:  2002-06-13       Impact factor: 91.245

Review 2.  Cardiac resynchronization therapy: the issue of non-response.

Authors:  Luigi Padeletti; Alessandro Paoletti Perini; Edoardo Gronda
Journal:  Heart Fail Rev       Date:  2012-01       Impact factor: 4.214

3.  Impaired renal function is associated with echocardiographic nonresponse and poor prognosis after cardiac resynchronization therapy.

Authors:  Rutger J Van Bommel; Sjoerd A Mollema; C Jan Willem Borleffs; Matteo Bertini; Claudia Ypenburg; Nina Ajmone Marsan; Victoria Delgado; Ernst E Van Der Wall; Martin J Schalij; Jeroen J Bax
Journal:  J Am Coll Cardiol       Date:  2011-02-01       Impact factor: 24.094

4.  Survival with cardiac-resynchronization therapy in mild heart failure.

Authors:  Ilan Goldenberg; Valentina Kutyifa; Helmut U Klein; David S Cannom; Mary W Brown; Ariela Dan; James P Daubert; N A Mark Estes; Elyse Foster; Henry Greenberg; Josef Kautzner; Robert Klempfner; Malte Kuniss; Bela Merkely; Marc A Pfeffer; Aurelio Quesada; Sami Viskin; Scott McNitt; Bronislava Polonsky; Ali Ghanem; Scott D Solomon; David Wilber; Wojciech Zareba; Arthur J Moss
Journal:  N Engl J Med       Date:  2014-03-30       Impact factor: 91.245

5.  Radiofrequency ablation of premature ventricular ectopy improves the efficacy of cardiac resynchronization therapy in nonresponders.

Authors:  Dhanunjaya Lakkireddy; Luigi Di Biase; Kay Ryschon; Mazda Biria; Vijay Swarup; Yeruva Madhu Reddy; Atul Verma; Sudharani Bommana; David Burkhardt; Raghuveer Dendi; Antonio Dello Russo; Michela Casella; Corrado Carbucicchio; Claudio Tondo; Buddhadeb Dawn; Andrea Natale
Journal:  J Am Coll Cardiol       Date:  2012-09-19       Impact factor: 24.094

6.  Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT).

Authors:  Ilan Goldenberg; Arthur J Moss; W Jackson Hall; Elyse Foster; Jeffrey J Goldberger; Peter Santucci; Timothy Shinn; Scott Solomon; Jonathan S Steinberg; David Wilber; Alon Barsheshet; Scott McNitt; Wojciech Zareba; Helmut Klein
Journal:  Circulation       Date:  2011-09-06       Impact factor: 29.690

7.  Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.

Authors:  J A Cairns; S J Connolly; R Roberts; M Gent
Journal:  Lancet       Date:  1997-03-08       Impact factor: 79.321

8.  Characteristics of heart failure patients associated with good and poor response to cardiac resynchronization therapy: a PROSPECT (Predictors of Response to CRT) sub-analysis.

Authors:  Rutger J van Bommel; Jeroen J Bax; William T Abraham; Eugene S Chung; Luis A Pires; Luigi Tavazzi; Peter J Zimetbaum; Bart Gerritse; Nina Kristiansen; Stefano Ghio
Journal:  Eur Heart J       Date:  2009-08-30       Impact factor: 29.983

9.  Association between frequency of atrial and ventricular ectopic beats and biventricular pacing percentage and outcomes in patients with cardiac resynchronization therapy.

Authors:  Martin H Ruwald; Suneet Mittal; Anne-Christine Ruwald; Mehmet K Aktas; James P Daubert; Scott McNitt; Amin Al-Ahmad; Christian Jons; Valentina Kutyifa; Jonathan S Steinberg; Paul Wang; Arthur J Moss; Wojciech Zareba
Journal:  J Am Coll Cardiol       Date:  2014-09-09       Impact factor: 24.094

10.  Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure: is a goal of 100% biventricular pacing necessary?

Authors:  Bruce A Koplan; Andrew J Kaplan; Stan Weiner; Paul W Jones; Milan Seth; Shelly A Christman
Journal:  J Am Coll Cardiol       Date:  2009-01-27       Impact factor: 24.094

View more
  5 in total

Review 1.  Non-response to Cardiac Resynchronization Therapy.

Authors:  Syed Yaseen Naqvi; Anas Jawaid; Ilan Goldenberg; Valentina Kutyifa
Journal:  Curr Heart Fail Rep       Date:  2018-10

2.  Postimplantation ventricular ectopic burden and clinical outcomes in cardiac resynchronization therapy-defibrillator patients: a MADIT-CRT substudy.

Authors:  Anne-Christine Ruwald; Mehmet K Aktas; Martin H Ruwald; Valentina Kutyifa; Scott McNitt; Christian Jons; Suneet Mittal; Jonathan S Steinberg; James P Daubert; Arthur J Moss; Wojciech Zareba
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-09-20       Impact factor: 1.468

Review 3.  [Management of premature ventricular ectopy in cardiac resynchronization therapy : Treatment strategies for an optimized cardiac resynchronization].

Authors:  Benjamin Rath; Julia Köbe; Florian Reinke; Lars Eckardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2021-01-29

Review 4.  The Ubiquitous Premature Ventricular Complex.

Authors:  Cameron Koester; Abdisamad M Ibrahim; Michelle Cancel; Mohamed R Labedi
Journal:  Cureus       Date:  2020-01-07

5.  Diagnostic and prognostic significance of premature ventricular complexes in community and hospital-based participants: A scoping review.

Authors:  Sukardi Suba; Kirsten E Fleischmann; Hildy Schell-Chaple; Priya Prasad; Gregory M Marcus; Xiao Hu; Michele M Pelter
Journal:  PLoS One       Date:  2021-12-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.